Lilly Partners With NIH to Test Olumiant in Patients Hospitalized With COVID-19

Source: FiercePharma

Drug companies worldwide are testing existing medicines as potential treatments for COVID-19—plus working on new therapeutics—with few answers yet. Now, Eli Lilly is among the latest to kick off a trial through a partnership with federal health officials, according to a FiercePharma report.

In conjunction with the National Institute of Allergy and Infectious Diseases, Eli Lilly is planning to test rheumatoid arthritis drug Olumiant in patients hospitalized with COVID-19. The study is starting this month in the U.S., and investigators eventually plan to expand testing to Europe and Asia. 

Read the full article.

Related Content